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Abstract: Prostate cancer (PC) is one of the most common cancers in men. The global burden
of this disease is rising. Its incidence and mortality rates are higher in African American (AA)
men compared to white men and other ethnic groups. The treatment decisions for PC are based
exclusively on histological architecture, prostate-specific antigen (PSA) levels, and local disease state.
Despite advances in screening for and early detection of PC, a large percentage of men continue to
be diagnosed with metastatic disease including about 20% of men affected with a high mortality
rate within the African American population. As such, this population group may benefit from
edible natural products that are safe with a low cost. Hence, the central goal of this article is to
highlight PC disparity associated with nutritional factors and highlight chemo-preventive agents from
medicinal plants that are more likely to reduce PC. To reach this central goal, we searched the PubMed
Central database and the Google Scholar website for relevant papers. Our search results revealed
that there are significant improvements in PC statistics among white men and other ethnic groups.
However, its mortality rate remains significantly high among AA men. In addition, there are limited
studies that have addressed the benefits of medicinal plants as chemo-preventive agents for PC
treatment, especially among AA men. This review paper addresses this knowledge gap by discussing
PC disparity associated with nutritional factors and highlighting the biomedical significance of
three medicinal plants (curcumin, garlic, and Vernonia amygdalina) that show a great potential to
prevent/treat PC, as well as to reduce its incidence/prevalence and mortality, improve survival rate,
and reduce PC-related health disparity.
Keywords: prostate cancer; health disparity; medicinal plant; chemoprevention
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1. Introduction
Prostate cancer (PC) is one of the most common cancers in men and its incidence continues to
rise in many developed countries [1]. Each year, PC causes nearly 30,000 deaths and 230,300 new
cases in the United States with the highest incidence and mortality rates among African-American
(AA) men [2]. The treatment options for PC care include surgery, radiotherapy, and chemotherapy.
However, surgery and radiotherapy are effective when the tumor is localized and detected during
the early stages. On the other hand, chemotherapy, while effective during the early stage tumor
development, often induces side effects. All these treatment strategies are ineffective once the tumor
has metastasized from the prostate to other parts of the human body. The majority of PC deaths may
be due to metastases that are highly resistant to current treatment options [3,4]. Even when PC is
treated, it usually comes back in the first few years post-treatment.
Androgens play a crucial role in the differentiation, development, and normal functioning of
prostate and, therefore, androgens may have an important role in developing prostate carcinogenesis.
Androgen deprivation therapy (ADT) administered though surgical or medical castration is currently
the standard treatment for men with locally advanced or metastatic prostate cancer [5]. Despite an
initial benefit of ADT alone or in combination with docetaxel chemotherapy, some prostate cancer
patients will progress to an advanced disease state termed as castration-resistant prostate cancer
(CRPC) [6]. CRPC is a lethal form of advanced disease for which treatment options are limited.
It depends on the androgen receptor (AR) function for which AR targeting remains the main therapeutic
intervention [6–8]. For most metastatic PC, ADT is usually not effective because prostate tumors may
regrow over time. In addition, ADT is often associated with several side effects that often influence
quality of life. The common side effects associated with ADT in men with metastatic cancer include hot
flashes, metabolic syndrome, osteoporosis, sexual dysfunction, gynecomastia, depression, and memory
difficulties [9–12]. Clinical trials demonstrated that a new generation of anti-androgen or novel
inhibitor targeting androgen synthesis is effective for post-docetaxel CRPC, which suggests that CRPC
at that stage is still, at least in part, dependent on the androgen/AR axis [13,14].
Since the treatment strategies for metastasized or locally advanced stages of PC are limited,
many PC patients rely on traditional medicine as viable therapeutic options [15]. Several neoplastic
drugs or chemotherapeutic agents used to treat PC patients have various side effects [16]. Vegetables
and fruits are the best known anti-cancer agents that contain a wide variety of different micronutrients
with properties that could make it more difficult for cancer to develop. These micronutrients
are polyphenols, flavonoids, carotenoids, vitamins, minerals, and other phytochemicals [17].
Eating vegetables and fruits containing high levels of polyphenols and flavonoids contributes to
PC prevention. According to several studies and a report from our lab, a poor diet may contribute to
approximately 10% to 75% of various cancer-related deaths (Figure 1) [18]. As seen in Figure 1, if a
man is eating a healthy diet rich in vegetables and fruits, he can reduce his risk of getting PC by 75%.
A study reported that Asian populations have a relatively low incidence rate of PC compared
to whites and black Americans because they use the extract of medicinal plants against cancer [19].
In general, scientific evidence from epidemiological studies suggests that consumption of high fiber,
lean protein, and low fat together with high vegetables and fruits significantly reduces the overall
cancer risks [20,21]. However, there is a strong scientific report indicating that nutrients in fruits and
vegetables may not reduce the risk of cancer when consumed as supplements. These supplements
are harmful and have toxic effects if taken at high doses [22,23]. Many people living in developing
countries have been using medicinal plants for many years to maintain their health and meet their
primary healthcare requirements due to limited access to medical doctors, poor socioeconomic
status, limited screening, and a shortage of nurses [24–26]. The phytochemicals present in medicinal
plants contain anticancer properties that help kill tumor cells, boost the human immune system,
and promote good health [27]. Taxol and polyphenols identified from medicinal plant species are
currently used in clinical settings to treat cancer. Scientific data have demonstrated that medicinal
plants prevent cancer by creating an unfavorable environment for cancer cells to grow, by preventing
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the recurrence of cancer, by improving the body’s immune system, and by reducing the side
effects of conventional treatments [28,29]. There are limited scientific reports that have addressed
the benefits of medicinal plants as chemo-preventive agents for PC especially among AA men.
This review paper addresses this knowledge gap by discussing PC disparity associated with nutritional
factors and highlighting the biomedical significance of three medicinal plants (curcumin, garlic,
and Vernonia amygdalina) that possess anti-cancer properties capable of preventing PC development
and progression. These chemo-preventive agents have the potential to prevent PC development, as
well as reduce its incidence and mortality rates, improve the survival rate, and reduce PC-related
health disparity.

Figure 1. Estimation of cancer-related deaths associated with a poor diet. Eating a plant-based diet
rich in vegetables and fruits has proven to significantly reduce cancer risk.

2. Approaches
The study was carried out to review and discuss scientific information on PC disparity in
the United States, and to highlight biomedical significance of three medicinal plants that have
been consumed for many years for the prevention and/or treatment of cancer and other diseases.
We performed a search on the PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/) database and
the Google Scholar website. Our searches included a combination of key terms such as: “medicinal
plant, prostate cancer prevention, racial disparity, and AA men”. From the key term searches, we were
able to identify peer-reviewed articles that have reported invaluable information about edible medicinal
plant products and their application towards the prevention and/or treatment of PC. We only reviewed
recently published scientific data and selected works cited between 2000 and 2017.
3. Results and Discussions
This review paper highlights, for the first time, the most commonly used edible medicinal plants
as natural chemo-preventive agents for preventing and/or treating PC. Developing countries have
fewer reported cases of PC while developed countries like the United States have higher reported
cases of PC with the largest incidence and mortality among black men worldwide. Humans have
relied on natural plant products to prevent and/or treat diseases for 1000 years and we use this idea as
the starting point to investigate the medicinal properties of curcumin, garlic, and Vernonia amygdalina
for preventing and/or treating PC. Based on the scientific data available in the literature, curcumin,
garlic, and Vernonia amygdalina are promising chemo-preventive agents. They possess a wide range
of health benefits including the maintenance of good health, the maintenance of a healthy immune
system function, and the prevention and/or treatment of the disease. PC patients living in both poor
and wealthy countries frequently used curcumin, garlic, and/or Vernonia amygdalina to prevent and
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treat cancer and other diseases. In the following discussion, we focused on PC disparity associated
with nutritional factors and chemo-preventive effects of the three medicinal plants.
4. Prostate Cancer Disparity in the United States
Prostate cancer (PC) is the second leading cause of non-cutaneous cancer-related deaths among
males living in the United States [30]. Despite an increased emphasis on early detection through
prostate specific antigen (PSA) screening, advanced early treatment, and improved understanding of
the prostate cancer risk factors, the disparity remains. AA men have continued to have the highest
mortality and lowest survival of prostate cancer, and all cancers combined [31–33]. On the contrary,
the mortality rate of PC has consistently declined among white men and other ethnic groups in the
United States [34]. The overall disparity in cancer between AA and Caucasian men accounts to about
40% of PC [35]. The possible reasons for this racial/ethnic disparity are not completely understood.
However, factors such as race, genetics, age, poor diet, and physical inactivity may contribute to
the occurrence of PC. In the following sessions, we discuss nutritional factors (diet, obesity, tobacco,
alcohol, and physical exercise) that are associated with a socioeconomic status for PC, which are more
likely to affect AA men when compared to any other ethnic groups. Figure 2 shows nutritional risk
factors that are more likely to contribute to PC disparity.

Figure 2. Nutritional risk factors associated with PC disparities. Poor diet, obesity, physical inactivity,
excessive cigarette smoking, and high alcohol consumption seem to rise the overall risk of getting PC
especially among AA men.

4.1. Dietary Factor in Prostate Cancer Disparity
Poor diet and obesity have long been considered as possible risk factors for PC. Several lines of
research have shown the association between animal fat such as red meat consumption and diagnosis of
PC especially among AA men [36,37]. The Asian population living in Asia and the United States exhibit
the lowest frequencies of PC because they commonly consume soybeans [38]. The organic compounds
(isoflavones) that are present in soybeans are thought to have a potential protective effect against
PC [39]. The purified form of soy isoflavones are tested in a clinical trial as a potential dietary agent
against the PC burden among white and African-American men in North America [40]. By testing the
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hypothesis that differences in PC incidence among different ethnic groups may be due to dietary factors,
scientists have investigated the impact of diet and obesity on risk in a population-based, case-control
study. In this study, they recruited 3162 men at nine military medical centers in the United States
including men who have prostate cancer and have a radical prostatectomy, and pathological data such
as the stage of cancer and the Gleason score, age, race, height, weight, and PSA level. They found
that more AA men are obese when compared to white men. AA men were also more likely to have a
higher PSA level, more advanced cancers, and positive surgical margins compared to white men [41].
In another study, a group of researchers in Michigan looked at a link between prostate cancer and the
metabolic syndrome. They recruited 637 prostate cancer patients and 244 control subjects. They found
that the metabolic syndrome was only marginally-related to an increase of PC in AA [42]. Several
studies have provided scientific evidence showing that obesity is associated with high-grade PC,
PC progression, and PC mortality [43–45]. A study conducted by the Prostate Cancer Prevention
Trial among 10,258 men undergoing biopsy found that obesity increases the risk of high-grade PC
but decrease the risk of low-risk grade PC [43]. In addition, obesity has been shown to be correlated
with lower rates of PC relapse-free survival and poor tumor characteristics among black but not white
men in the United States [44]. Although several studies have shown that obesity is associated with an
increased risk of prostate cancer [46,47], other studies did not find an association between obesity and
PC development [48–51]. A cohort study of 69,991 men found that those with high body mass index
(BMI) are at increased risk of high grade and fatal PC. However, BMI is less likely to be associated
with low grade PC [52]. Giovannucci et al. (2003) showed an inverse relationship between obesity and
PC risk, but only for men under 60 years of age who have a family history of cancer [53].
4.2. Tobacco and Alcohol Factors in Prostate Cancer Disparity
Like many malignancies, tobacco and alcohol are well-known risk factors for PC. Studies indicated
that cigarette smoking is associated with high-grade PC, incidence, and mortality among men [54,55].
However, there are limited studies that have focused on AA men. A study from the Centers for Disease
Control and Prevention (CDC) indicated that AA and Caucasian men both have a 21% prevalence of
cigarette smoking [56], but AA men have lower rates of heavy smoking and lower rates of smoking
cessation [57–60]. A multi-ethnic study by Adams et al. (2013) found that about 21% of AA men
were heavy smokers compared to 30.5% of Caucasian men [61]. There are limited studies that have
addressed the association between alcohol drinking and PC disparity. However, heavy alcohol drinking
is associated with breast cancer, colon cancer, esophageal cancer, larynx cancer, oraparyngeal cancer,
liver cancer, and pancreatic cancer [62,63].
4.3. Physical Activity Factor in Prostate Cancer Disparity
A study by Clarke and Whittemore (2000) indicated that AA men who are physically inactive are
3.6 more likely to be diagnosed with PC compared to AA men who are physically active [64]. However,
physical activity has not been shown to lower the incidence of PC among Caucasian men [65,66].
This significant racial disparity may be due to the presence of lower levels of tumor promoting growth
factors among AA men who exercise.
4.4. Geographic Factor in Prostate Cancer Disparity
Diet is considered to play a crucial role in the geographical differences in PC incidence and
mortality. The incidence rate of PC in Africa where most people consume high plant-based food is
approximately four times lower when compared to the United States where most people consume
high protein and fatty dairy products [2,66]. For example, the number of new cases of PC was 52 per
100,000 men in 2012 in Africa while in the United States; the number of new cases of PC was 233 per
100,000 during the same period. The reason for the highest incidence of overall PC in the wealthy
nations is that the Western diet is characterized by animal fat, high consumption of energy and meats,
and low intake of fiber [67]. The incidence rate of PC is relatively lower in people living in India,
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China, Asia, and the East Mediterranean region [22]. Although the incidence rate of PC is lower in
less developed countries, the mortality rate is higher when compared to wealthy nations. Meanwhile,
the mortality rate of PC remains significantly high in predominantly black men worldwide than
any other ethnic groups [66]. Several therapeutic options have been recommended to deal with the
treatment of PC among AA men [68,69].
4.5. Socioeconomic Status in Prostate Cancer Disparity
It has been hypothesized that differences in PC disparity are associated with one’s socioeconomic
status. The American Cancer Society predicts that one in every nine men living in the United States
will be diagnosed with PC during their lifetime. This number increased with age, which suggests that
about six in every 10 men in the United States aged 65 years or older will be diagnosed with PC over
their lifetime [70]. AA men are disproportionally affected when compared to other racial groups [71,72].
One of the potential explanatory factors associated with PC disparity between Black/AA and Caucasian
men is the inequality in socioeconomic status (SES) [73]. The SES could be measured by assessing the
differences in the level of education and income, access to healthcare and fresh foods, and residential
segregation [74]. Studies from the surveillance and epidemiology end results (SEER) database of men
in California highlighted that PC patients with a low socioeconomic status usually have poor health
insurance coverage, which may reduce their accessibility to cancer screening services and lead to
late diagnosis, treatment, and worse mortality outcome [75,76]. Poverty was also associated with
the lack of adequate health coverage, follow-up, and diagnosis in the advanced stage [76]. Weinrich
and his collaborators reported that AA men have a low PC screening due to several barriers such
as absence of health insurance, no sense of urgency, poor information on medical professional, cost
of care, and lack of routine screening from a primary healthcare physician [77]. The majority of the
black population compared to other ethnics/racial groups in the US stays in neighborhoods with
poor quality and access to clean water and fresh food, transport, recreational facilities, and high
insecurity [78,79]. This inaccessible to fresh food leads to their lower consumption of a plant-based
diet. Meanwhile, fruits and vegetable possess phytochemicals and antioxidants that may prevent PC
development [73,80]. On the other hand, lack of recreational parks and violence reduced the level of
physical activity, outdoor activity, and increased the rate of obesity and stress [72].
4.6. Oxidative Stress and Age Factors in Prostate Cancer Disparity
The risk of developing PC increases gradually with age. Older men have the highest incidence of
PC and African American (AA) men are disproportionately affected than any other ethnic groups [81,
82]. The probability of developing PC has increased from 0.005% in males younger than 39 years to
2.2% in males between the ages 40 to 50 and approximately 13.7% in males between 60 to 79 years
of age [83,84]. The PC is diagnosed at a younger age among AA men and they are approximately
four times more likely to die from this disease compared to white men [82,85]. Based on this PC
disparity, life expectancy of AA men is shorter compared to non-Hispanic white men in the United
States [86]. The literature reveals a strong connection between oxidative stress, age, and PC. PC is
commonly associated with a shift in the antioxidant-pro-oxidant balance towards increased oxidative
stress. According to the free radical theory of aging, oxidative stress is blamed for aging because of
the negative impacts excessive free radicals and/or the reactive oxygen species (ROS) have on the
cells [87]. This phenomenon can be explained by the fact that older cells seem to be more susceptible to
intracellular conditions that produce excess ROS, which induce tumorigenesis [88]. In addition, there is
a decrease of antioxidant defense in the old population of men with PC [89]. Scientific data revealed
that a shift in the pro-oxidant-antioxidant status in prostatic tissue of cells, animals, and humans
played an important role in the initiation of prostate carcinogenesis [81].
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5. Chemo-Preventive and Therapeutic Effects of Curcumin on Prostate Cancer
Curcumin (diferuloylmethane) is a polyphenolic compound derived from the rhizome of
the plant Curcumin longa commonly known as turmeric. This compound has been widely
used for centuries as a spice in Asia and the Middle East cuisine and as ayurvedic medicine
due to its anti-oxidative, anti-inflammatory, and antiseptic properties [90]. Mounting evidence
supports the unique chemo-preventive and therapeutic potential of curcumin. Many reports have
shown that curcumin could inhibit initiation, progression, and metastasis of a variety of tumors
including PC [91,92]. In PC, curcumin treatment has been shown to inhibit proliferation of both
androgen-sensitive and androgen-independent PC cells [93,94]. Curcumin was shown to inhibit
growth and proliferation of LNCaP and PC-3 cells in vitro [94,95] and in the xenograft model [94].
This inhibition of cell proliferation has been found to be associated with increased apoptosis [95–97].
Curcumin treatment was also found to prevent metastasis of PC cells in many studies [98–103].
In addition, curcumin was demonstrated to inhibit angiogenesis in nude mice when they were
injected with LNCaP and received a diet supplemented with curcumin [96]. Several scientific studies
demonstrated that curcumin and its analogues exert anti-cancer effects on prostate cancer models
including its effects on androgen receptor (AR) signaling and numerous downstream targets [104–106].
Another study indicated that curcumin analogues inhibited AR activity in prostate cancer cells [107].
Joseph et al. (2013) demonstrated that curcumin downregulated AR expression, limited AR binding to
the androgen response element of the prostate specific antigen (PSA) gene, and reduced the expression
of PSA in LNCaP cells [108]. Other studies demonstrated curcumin effectively delayed tumor growth
and suppressed AR expression in an LNCaP xenograft model [109,110].
Some of the known anti-cancer effects of curcumin are mainly mediated through its negative
regulation of a plethora of transcription factors, growth factors, inflammatory factors, protein kinases,
and other oncogenic molecules. Curcumin was shown to down-regulate the expression and activity
of androgen receptors [111,112] and co-factors [113] in LNCaP and PC-3 cells, which leads to growth
inhibition. Curcumin was also shown to suppress the NF-kB activation and to downregulate the
expression of both Bcl-2 and Bcl-xL in DU145 cells and LNCaP cells, which results in activation of both
caspase-8 and caspase-3 as well as apoptosis [114]. Inhibition of cyclins [115,116] and upregulation of
cyclin dependent kinase inhibitors [116] together with the increase in apoptosis were observed when
PC cells were treated with curcumin. Curcumin was demonstrated to prevent metastasis in prostate
cancer as well. When the metastatic C4-2B PC cells exhibit a tropism to bone and were injected in
immunocompromised mice, curcumin treatment prevented the establishment of metastases in bone.
This prevention appeared to be modulated by the induction of the expression of bone morphogenic
protein-7 (BMP-7), which results in upregulation of the brown/beige adipogenic differentiation
program implicated in the inhibition of bone metastasis [99]. Additional mechanisms by which
curcumin prevents prostate metastasis involve suppression of cancer associated fibroblast-induced cell
invasion [102], downregulation of the inflammatory cytokines CXCL1 and CXCL2 [117], and inhibition
of the secretion of matrix metalloproteins [101,103]. In its control of angiogenesis, curcumin was
found to significantly reduce micro-vessel density in a xenograft model. Curcumin has shown great
promise in clinical trials as well [118]. Curcumin in combination with isoflavones was shown to
reduce the levels of PSA in the serum of participants who had a serum PSA level above 10 ng/mL,
which suggests a synergistic role of curcumin with isoflavones to reduce PSA production [119]. Many
clinical trials are at different stages to investigate the therapeutic benefits of curcumin as a potential
drug for many diseases. With its very limited side effects even at high doses and its pleitropic effects
on many signaling pathways, curcumin represents an attractive drug that could be effective alone or
in combination with other drugs in the management of multi-genic human diseases.
6. Chemo-Preventive and Therapeutic Effects of Garlic on Prostate Cancer
Epidemiological studies suggest that high intake of garlic has protective effects against
several human cancers including PC and the protection is even higher with increased intake [120].
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The chemo-preventive effects of garlic are supported by several scientific studies. A report indicated
that garlic possesses anti-cancer properties with the ability to prevent the growth of PC cells and
enhance the immune system [121]. Garlic (Allium sativum) is a nutritious plant used for thousands
of years as spices or seasoning, which is commercially available in the market in the form of
garlic oil, garlic powder, or garlic extract [120,122]. It is also a medicinal agent that is composed
mainly of water, carbohydrates, fiber, vitamin C, and minerals such as potassium, iron, magnesium,
and phosphorus [122]. Flavonoids, saponins, proteins, and sapogenins are the most abundant
phenolic compounds present in garlic [123,124]. Allicin, allixin, diallyl sulfide, diallyl disulfide,
diallyl trisulfide, S-allylcysteinene allylmercaptan, allylmethyldisulfide, and ajoene are the dominant
bioactive compounds present in garlic. These bioactive compounds act as chemo-preventive agents
and their mechanisms of action include cell growth inhibition, cell cycle arrest, reactive oxygen species
destruction, protein expression disruption, and induction of apoptosis [125–127]. These suggest that
the consumption of garlic may be associated with a decreased risk of PC development. Epidemiological
research from a population-based case-control study has revealed that men who consume garlic daily
at the minimum dose of 10g/day have a lower risk of developing prostate cancer compared to men
who consume less than 2.2 g/day [120]. Both in vitro and in vivo experiments have shown that garlic
contains a specific anti-invasive compound capable of suppressing tumor growth in the prostate cancer
cells and significantly prolonged life in the mouse test model [120,121]. Studies done by Kim and his
colleagues showed that the diallyl trisulfide (DTAs) compound derived from garlic extraction induced
apoptosis in the PC-3, LNCaP PC cell lines, and Transgenic Adenocarcinoma Mouse Prostate mice
were exposed to 20 and 40 µmol/L for 8 and 16 hours [128]. In the same pattern, another research
study found that DATs induced cell cycle arrest during the G2/M phase, decrease the expression of
CDK1 and Cdc25C proteins, increase the cyclin B1, Bax, and Bak proteins in the PC-3 cells, and inhibit
the intro cell migration [126–128]. A scientific report from our laboratory demonstrated that garlic
extract inhibits the proliferation of human leukemia (HL-60) cells by producing malondialdehyde
(a biomarker of cellular injury) and inducing apoptosis through the phosphatidylserine externalization
and caspase-3 activation [129]. In summary, garlic could be viewed as a promising chemo-preventive
agent against PC due to his ability to execute cell death through various signaling pathways.
7. Chemo-Preventive and Therapeutic Effects of Vernonia amygdalina on Prostate Cancer
Vernonia amygdalina, which is commonly called bitter leaf in English, is a medicinal plant that
possesses many micro-nutrients important for the maintenance of human health and prevention of
various diseases. It is widely consumed in Cameroon for nutritional purposes and has been used
for many decades as ethno-medicine under the recommendation of herbalists for treating certain
diseases and disorders including stomach discomfort, vomiting, malaria, diarrhea, and intestinal
illnesses [130]. Furthermore, it has been used in Africa for preventing and treating diabetes,
tuberculosis, measles, infertility in women, and hyperlipidemia [131–133]. Studies have revealed the
presence of phytochemicals such as sesquiterpene lactones (vernolide, vernodalol), anthraquinones,
flavonoids, lignans, phenolic acids, terpenes, and xanthones in Vernonia amygdalina and other Vernonia
species [134,135]. These phytochemicals found in Vernonia amygdalina and other Vernonia species
are good antioxidants. According to Khlebnikov et al. (2007), an antioxidant is any substance that
can prevent, delay, or eliminate oxidative damage of a target molecule, and act as a regulator of the
antioxidant defense [136]. Antioxidants from fruits and vegetables provide nutrients that support a
healthy immune system and fight against cancer. At present, there are limited studies in the literature
about the benefit of medicinal property of Vernonia amygdalina to PC patients. However, preliminary
data and recently published studies from our laboratory have demonstrated that Vernonia amygdalina
Delile acts as an antioxidant at a low dose and as pro-oxidant at a high dose when exposed to
human prostate cancer (PC-3) cells [137]. In addition, we have demonstrated that the mechanisms
involved in the chemoprevention of prostate cancer by Vernonia amygdalina Delile are mediated
by inhibiting cell growth arrest, oxidative stress, DNA damage, and apoptosis, which is shown as
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phosphatidylserine externalization, activation of caspase-3, and cellular morphological changes [137].
Collectively, we have demonstrated the therapeutic effect of Vernonia amygdalina Delile on human
prostate cancer (PC-3) cells. Our laboratory is currently testing the chemotherapeutic effects of
Vernonia amygdalina Delile’s biologically active ingredient to elucidate its underlining mechanism
of action in vitro and in vivo. Other Vernonia species such as Vernonia divaricate possess anticancer
agents that significantly retard the growth of cancer cells including acute promyelocytic leukemia
(HL-60) cells, human breast adenocarcinoma (MCF-7) cells, and PC-3 human prostate cancer cells [138].
Another study indicated that Vernonia amygdalina inhibited PC cells, but have no effect on normal
human peripheral blood mononuclear cells [139]. Working with cell culture models and transgenic
mouse models, our lab has also demonstrated that Vernonia Amygdalina exerts chemo-preventive
action against breast cancer cells by targeting mechanisms that involve the arrest of cancer cell growth,
the induction of DNA damage, and apoptosis accompanied by secondary necrotic cell death [129,130].
8. Summary of Chemo-Preventive and Therapeutic Effects of Curcumin, Garlic,
and Vernonia amygdalina on Prostate Cancer
Curcumin, garlic, and Vernonia amygdalina are used worldwide in a variety of dishes. There are
several epidemiological studies demonstrating their benefits and effects against cancers including PC.
These medicinal plants exert their chemo-preventive and therapeutic effects on PC through several
mechanisms of action (Table 1).
Table 1. Chemo-preventive and therapeutic effects of curcumin, garlic, and Vernonia amygdalina on
prostate cancer.
Edible
Medicinal Plants

Medicinal Uses

Pre-Clinical Studies

Curcumin

People use curcumin to prevent
and/or treat cancer, Alzheimer,
erectile dysfunction, baldness,
hirsutism, and fertility

Inhibition of
proinflammatory NF-B,
reduction of prostate
cancer growth, induction
of apoptosis

Clinical trials needed

Garlic
(Allium sativum)

People use garlic to prevent
and/or treat many conditions
including prostate cancer, breast
cancer, rectal cancer, stomach
cancer, colon cancer, yeast
infection, high blood pressure,
hepatitis, and diabetes.

Cell growth arrest, cell
cycle arrest, DNA
damage, protein
expression disruption,
and induction
of apoptosis

Few clinical trials have
been performed, but
they are still inconsistent.
Recognition of garlic as
one of the vegetables
with potential
anti-cancer properties

People use Vernonia amygdalina
to prevent and/or treat fever,
Vernonia amygdalina
hiccups, kidney problem,
gastritis, enteritis, malaria,
and rheumatism

Cell growth arrest, DNA
damage, and induction
of apoptosis as
evidenced of
phosphatidylserine
externalization,
activation of caspase-3,
and cellular
morphological changes.

Clinical Studies

Clinical trials needed

Summary & References
Curcumin has
demonstrated the
potential to slow growth
and kill prostate
tumor cells
References
[98–101,103,115].
High consumption of
garlic lowers the risk of
prostate cancer. Sulfur
present in garlic
neutralizes cancer cells
and shrinks the tumor
References
[120,121,126,128].
Limited scientific
evidence. May act both
as antioxidant and
pro-oxidant depending
on the dose. Further
research needed.
References [137,139].

9. Molecular Mechanisms of Action of Medicinal Plants (Curcumin, Garlic,
and Vernonia amygdalina)
Figure 3 shows the common molecular mechanisms by which curcumin, garlic,
and Vernonia amygdalina exert their anti-cancer activity in cancer cells. As shown in Figure 3,
curcumin, garlic, and Vernonia amygdalina inhibited cell growth or caused cell growth arrest through
the induction of DNA damage, expression of stress genes (p53, p21, Bax, and CDK cyclin complex),
impact of cell cycle arrest, and triggered apoptosis by modulating phosphatidylserine externalization,
activation of caspase-3, and nucleosomal DNA fragmentation.
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Figure 3. Schematic representation of common molecular mechanisms of curcumin, garlic,
and Vernonia amygdalina as therapeutic agents in the management of malignancies.

10. Conclusions
Prostate cancer (PC) remains a global public health issue in the United Sates, especially
in African-American men who have a high mortality rate of PC compared to other racial
groups. The treatment strategies for PC are limited, and chemoprevention is key to its future
management. To overcome the burden of PC, scientists have made considerable progress by
identifying plant-based foods that have chemo-preventive and therapeutic effects. In this research,
we have reviewed extensively the biochemical properties and medicinal values of curcumin, garlic,
and Vernonia amygdalina for their use in PC prevention and/or treatment. Consumption of these
three medicinal plants contributes significantly to the prevention of PC. They are rich in vitamins,
minerals, and phytochemicals such as flavonoids that are known to reduce the risk of PC. In addition,
phytochemicals in these natural products are more likely to not only prevent PC development, but also
reduce its incidence and mortality rates, improve the survival rate, and reduce racial disparity in PC.
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Acknowledgments: We thank the Research Centers in Minority Institution (RCMI)-Center for Environmental
Health and the Center of Excellence in Minority Health and Health Disparities at Jackson State University for
their support of this work.
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